Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Exploring Alternatives Following News of Acquisition Bid

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Millipore said late last night that its board of directors is evaluating "strategic alternatives to enhance shareholder value," including a potential merger or sale of the company.

Millipore's statement comes two days after Bloomberg reported that Thermo Fisher Scientific had made a $6 billion bid for the firm. Millipore did not respond to a request from GenomeWeb Daily News for comment earlier this week, while Thermo Fisher officials said they would not comment on rumors.

Millipore confirmed that it has hired Goldman Sachs as its financial advisor and Cravath, Swaine & Moore as its legal advisor to assist the board in its evaluation.

Millipore also said that it has not set a timetable for completing the evaluation and cannot assure that it will lead to any transaction.

In early Wednesday trade on the New York Stock Exchange, shares of Millipore were up 3 percent at $91.50. Its shares are up 28 percent for the week.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.